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CLINICAL TRIALS, A SCIENTIFIC DISCIPLINE*
HARVEY BLANK, M.D.
"Assuredly we bring not innocence into the world,
we bring impurity much rather: that which purifies
us is trial, and trial is by what is contrary."
—John Milton
The practice of medicine including dermatology
has been undergoing a great change for which we
practitioners were not well prepared. In 1960
alone the Food and Drug Administration ap-
proved 165 new drugs for human use in the United
States (3). This avalanche of potent and often
novel therapeutic agents now makes it possible
for the physician frequently to have a profound
and definitive effect on his patient's illness. If
the drugs are to benefit rather than to harm or
to waste money, they must be used with wisdom
based upon sound information.
Facts learned in medical school about thera-
peutic agents are soon inadequate and out of
date. It has been said that: "The facts of medicine
are (1) that there are few if any facts in it, and
(2) that which passes for fact—that is, interpre-
tation of currently available data—must be
reexamined frequently" (14). In Table 1 is a
list of drugs reported with enthusiasm in past
years as of distinct benefit in the treatment of
herpes zoster which now are known to have
only a placebo effect upon the course of the
disease. In order to practice good medicine it
has become essential for each physician to learn
the important properties and uses of many new
drugs each year. The most important aspects
and yet the most difficult to judge are the effects
of a drug in human patients. It is essential that
not only those who carry out and report clinical
trials be thoroughly familiar with modern
technics but also those who read and judge the
results be equally familiar with the pitfalls of
clinical evaluations. Before he can practice his
art, the practitioner must often disentangle a
maze of conflicting opinion. Only recently have
sound guides been published for both investi-
gator and reader (8, 19, 22).
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The purpose of a clinical trial is to get reliable
information and reproducible data by objective
evaluation of the patient's response. The evalua-
tion of the effects of drugs in man is by no
means simpler, nor does it permit a less rigorous
method of examination than the formal experi-
ment with the laboratory animal (8, 18). The
basic goals are the same as when one studies
in vitro phenomena but the multitude of factors
which complicate experiments in humans neces-
sitate even greater care by the investigator in
performing the study and in judging the results.
it is becoming clear that a sound clinical trial
requires a high degree of sophistication not only
in clinical medicine but also in the methods of
scientific research. It is evident particularly from
the reports of drug assessments that many
physicians lack the critical judgment or the
basic research experience to do reliable work of
this kind. Only now are medical students being
taught elementary statistics and the weighing
of evidence; the rest of us must learn the meth-
odology of this new strict discipline from recent
published sources. That good clinical trials are
difficult to accomplish is clear from their relative
rarity in an otherwise staggering literature. As
yet the number of noteworthy studies do not
seem to exceed the editorial exhortations on the
subject (4, 5, 7, 8, 14).
A clinical trial is always a form of comparison.
Even when the investigator fails to include a
control, one is always implied and serves as a
basis for the judgment of any drug. The only
important question about the control is there-
fore not whether it is present, but whether it is a
sound basis for comparison (8). In the past, too
many articles on therapy in dermatology were
based on "historical controls", although the
authors usually failed to recognize them as
such. A typical study of this sort is one in which
all patients received the same treatment and
which then reports the number of patients who
"recovered, improved, or failed to improve"
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TABLE 1
Drugs formerly used widely and reported of benefit
in herpes zoster which have only a placebo effect
in the disease
Aureomycin Protamide
Chioromycetin Sodium iodide I.V.
Ergotamine Terramycin
Gamma globulin Thiamine chloride I.V.
Pituitrin Vitamin B12-I.M.
TABLE 2
Sources of error introduced by the dermatologic
patient and his environment
Desire to get well or conversely to exploit his
illness.
Personal, emotional and social problems.
Changing ambient conditions: temperature,
humidity, sunlight, etc.
Variations in sweating.
Seasonal variations.
Presence or absence of secondary infection.
Personal habits of bathing.
Physical activity and occupation.
Failure to use medication or to use it properly.
Variations due to age, sex, race.
Variations in the natural course of the disease.
Intolerance to the vehicle.
from the treatment. A comparison is implied
either with no treatment or some other form of
treatment. Because the investigator fails to
recognize and identify his controls and therefore
to eliminate placebo effects and bias, this is a
most treacherous method and the one most
likely to lead to erroneous conclusions. With
truly dramatic new drugs such as griseofulviri
there appears to be less need for placebo-treated
controls but as we shall see later even with this
agent a double-blind study was most revealing.
Many forces extraneous to the experiment act
to produce bias and introduce errors. These
vary in each patient and with each investigator
and differ at different times. Some of the factors
which can favorably or unfavorably affect a
clinical trial in dermatology are indicated in
Tables 2 and 3. Bias and errors cannot be eliini-
nated from clinical trials. However, by using
double-blind controls, randomization of patients,
well chosen placebos and other technics it is
possible to equalize these chance effects in a
way which does not favor medicament or placebo
(7, 18).
TABLE 3
Bias and errors introduced by the physician
Unconscious prejudice in issuing medication.
Failure to include subjects in truly random
fashion.
Errors of issuing properly or recording correctly.
Inadequate explanation of use, particularly
topic als:
Failure to instruct to rub in well or to apply
casually.
Failure to identify clearly for right and left
side trials.
Evaluation of results too infrequently.
Failure to use adequate criteria for evaluation.
Failure to differentiate between subjective and
objective response.
Desire to see improvement.
Excess of skepticism.
Preconceived ideas of medication's value.
The idea that a "medication" must be better than
ointment base alone or a placebo.
The simplest procedure is a "single-blind";
a comparison between the test drug and a
placebo or other control medication when the
investigator knows the identity of the prepara-
tions but does not reveal them to the patient.
it is often used in ordinary clinical practice, as
for example to determine whether tar or mercury
is superior for a patient's psoriasis, but rarely is
it reliable enough to use for a study worthy of
publication. A noteworthy exception is the
recent evaluation by Sinclair-Gieben and
Chalmers of the treatment of warts by hypnosis
in which the patients were told that the warts
only on one side would disappear. In those
subjects successfully hypnotized it was noted
that only those warts which had been the subject
of specific suggestion disappeared, whereas most
of the other "control" warts on the other side of
the body did not disappear.
If neither the investigator nor the patient
knows the identity of the drug being tested at
the time and the medications are identified by
code only, the procedure is known as "double-
blind". Unfortunately, no method is better than
the skill and care of the investigator (7). The
double-blind technic itself does not guarantee reli-
ability of data or validity of results. As Modell
and Houde (8) point out, it is being exploited by
some who even warn in their titles that they
used this special insurance to guarantee results
which are beyond reproach. Nonetheless, the
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inaccuracies of the conclusions of some studies
suggest that the blind will not lead the blind
unless the method somehow provides vision. One
must become keenly aware of the many sources
of error even in double-blind studies and con-
stantly guard against spurious results. For
example, in a recently published double-blind
study of an oral antipruritie tablet, the phy-
sician's secretary gave out the tablets supposedly
in a random fashion and kept the records. This
was intended to reduce to a minimum extraneous
sources of influence as the physician evaluated
the patient's response. At the completion of the
study when the code was opened it was found
that 19 patients had received inert tablets and
83 the drug. Obviously they had not been given
out in a random fashion and the bias introduced
casts doubt on the comparability of the treated
and the control groups. Although the authors'
conclusions may be correct they would have to
be considered as unproved.
The placebo properly used is the foundation of
most clinical trials. In a learned discussion of this
inert, blank, dummy medication, the New
Yorker magazine traces the derivation of the
word which was first used in medicine as some-
thing which meant more to please than to benefit
the patient (13). In 1937, Harry Gold and his
colleagues at Cornell first used the placebo in an
incisive modern fashion. A number of publica-
tions in recent years have made it clear that the
placebo does have remarkable and profound
effects in patients (1, 18, 19). The purpose of the
placebo is to provide a group of patients com-
parable to the drug-treated group in all respects
except the one (the active drug) that is being
investigated. In addition to giving surprising
relief from pain or itching, the properly used
placebo furnishes a measure of the course the
disease would take without the new drug. In
most clinical trials it is impossible to draw valid
conclusions without such a baseline for com-
parison. It is far better to compare a smaller
number of carefully treated patients with an
equal number in a placebo control group than
to include great numbers of uncontrolled cases
in a report. No matter who does the study,
quantity cannot substitute for quality in experi-
mental medicine.
In a recent "double-blind" study nine different
dermatologists treating 510 patients under what
seemed like ideal experimental conditions eon-
eluded with the help of an advanced statistical
analysis that topical steroids were no more
beneficial than the lotion base. This conclusion is
very puzzling because other studies, including
our own, have shown a regular superiority of
the steroid preparations over the base alone. It is
impossible at a distance to know why the report
came to, what in my judgment, is an erroneous
conclusion. I thought it of sufficient importance,
however, to suggest the following possible
difficulties which may adversely affect even a
double-blind controlied study in dermatology.
A study with a large number of patients, four
different preparations and many observers is
immensely difficult because of the constant close
supervision needed to have the instructions
carried out and the observations made with the
meticulous care which is required. A study of a
topical agent has to be much more painstaking
than one concemed only with swallowing pills.
For example: the medication intended for the
right side may be applied with the right hand to
the left side; or the directions are otherwise
misunderstood and the medication is not used
as the doctor intended; or other confusing
medications such as oral antibiotics are included
in the patients' care; or the patient may sit with
one side to the sun; or he may use some other
treatment obtained from a different source; or
the different recorders do not use comparable
criteria in the selection of patients and evaluating
results, and are not sufficiently instructed; or
nurses or technicians or secretaries make mis-
takes; etc. etc. Although the investigators
aliuded to, planned their clinical trial from its
beginning, as all texts advise, with an expert
statistician, they may have failed to take into
account all the biological and human problems
which hamper the collection of accurate informa-
tion. I do not disparage their statistical evidence,
for in the final analysis this is the only kind of
evidence we can possibly have (20). But the
value of statistics lies not in proof of the in-
vestigators' theses, for statistics prove nothing
absolutely; rather, they provide a method by
which, if the data are accurately collected and
recorded, he can often determine whether the
observations were artifacts or the results of
treatment. One of the important defects in the
double-blind technic is the ease with which
imprecise observations cause a reduction in real
differences between preparations. Good statistics
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TABLE 4
Side effects in a 16-week double-blind trial of griseo-
fulvin (from Frain-Bell and Stevenson)
Symptom or Sign
Patients
Receiving
Griseoful-
yin (37)
Patients
ReceivingInert
Tablets
(39)
Headache
Dyspepsia
Abdominal discomfort
Vomiting, nausea
Diarrhoea
Ulcers in mouth
Cramps in limbs
Flushing of face
Drowsiness
Fever
Lassitude
Nails more brittle
Rashes or itching
3
1
1
0
1
o
2
0
0
1
1
0
3
1
1
2
2
2
1
0
1
1
0
0
1
4
cannot salvage a bad experiment. The study of
topical steroids which disproves the now accepted
and obvious is reminiscent of another study
which concluded that aspirin was no better than
a placebo tablet when evaluated in patients seen
at intervals as out-patients. In contrast, how-
ever, in a study repeated in the hospital, a
bedside observer readily discriminated not only
between placebo and aspirin but also between
various doses of aspirin (8).
For the occasional spectacular drug, placebo-
treated controls may seem unnecessary. Griseo-
fulvin appeared to be such a drug. But even here
more accurate information about side-effects
probably was gained in the double-blind trial
reported by Frain-Bell and Stevenson (6)
(Table 4) than from reports of hundreds of
other patients treated by our group and many
others in uncontrolled studies. I, and perhaps
others, relearned the lesson of the value of
controls in any clinical trial.
In dermatology the investigator using a topical
agent has another problem in addition to the
powerful psychological effects created by any
medication; that is the soothing or cooling or
protective action which results from the vehicle
alone. Skin lesions have been responding for
many years to bland lotions, creams and oint-
ments. It is not surprising, therefore, that they
continue to get better following the application
of such locally inactive agents as vitamins in
topical medicaments. So many skin lesions
respond to the base alone that the careful in-
vestigative dermatologist often uses the right
and left comparison method. It is apparent from
Fig. 1, however, that not everyone is happy with
this technic. Nonetheless, by applying two
preparations identical except for the active
ingredient simultaneously to paired lesions of
equal severity and with a symmetrical dis-
tribution, it is often possible to obtain extremely
reliable data. Pillsbury, Sulzberger, Siemens and
many others have emphasized that in a me-
ticulously performed double-blind clinical trial
of this sort the troublesome variable factors in
the experiment should cancel out (10, 16, 17).
This will be illustrated a little later with a study
of topical steroids.
The first comparison of topical agents goes
back many years (9), even before the Yearbooks
of Dermatology were published. In 1536, fol-
lowing a battle, when Pare had no more scalding
hot oil to treat the remaining gunshot wounds,
he applied an ointment of rose oil, egg yolks and
turpentine. The next morning the absence of
the usual fever, pain and swelling in the ointment-
treated wounds as compared with those which
had received hot oil caused him to abandon the
latter forever. That he also knew the power of
Fia. 1
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TABLE 5
Double-blind paired comparison of varying concen-
trations of triameinolone acetonide lotions
0.5% better than 0.1% 3/10
0.5% equal to 0.1% 7/10
0.1% better than 0.01% 5/15
0.1% equal to 0.01% 10/15
the paired comparison technic is clear from his
observations the following year on a soldier
burned by gunpowder. He said: "I applied the
onions (a kind of poultice) to one side of his
face and to the other half medicines usually
applied to burns. At the second dressing I
observed the part dressed with the onions quite
free from blisters and excoriations, the other
being troubled by both, whereby I gave credit
to the (onion) medicine."
In addition to the right and left sided com-
parison technic, one can alternate the topical
agents in the same or different patients just as
one would with parenteral agents. Good ex-
amples of this have been reported by Polano and
his colleagues in comparing topical steroids and
to demonstrate that neomycin added to the
corticosteroid was actually beneficial (11, 12).
The alternating procedure seems to be more
time-consuming and difficult than the paired
technic but may be useful for certain studies.
In the last part of this report I should like to
show you some data on topical corticosteroids
obtained in our department by my colleagues and
myself. The studies were done in a double-blind
fashion using the right and left comparison
technic exclusively. Only skin lesions such as
eczematous or seborrheic dermatitis known to
respond were selected. A substantial number
were performed in the hospital where daily
observation was possible. In some instances
when the house officers noted an apparent
superiority of one code numbered preparation
over another, new codes were used to minimize
such prejudice. In most instances the lesions
responded favorably on both sides but by careful
objective examination, differences were noted
and recorded. As others have stated, eventually
even the slower to respond lesions usually catch
up. These results are presented for two reasons:
careful properly controlled studies of this type
will yield reliable information even in small
TABLE 6
Double-blind paired comparison of Triamcinolone
acetonide vs Hydrocortisone (lotions)
Tn-ac. Hydrocort.
0.1% better than 1.0% 75/109
0.1% equal to 1.0% 28/109
0.1% poorer than 1.0% 3/109
0.01% better than 1.0% 10/30
0.01% equal to 1.0% 18/30
0.01% poorer than 1.0% 2/30
numbers of patients with considerable precision,
and secondly the observations reported indicate
the likelihood of a considerable practical im-
provement in dermatologic therapy.
Table 5 summarizes our results which are
similar to those of others (2, 21) in comparing
the relative effectiveness of various concen-
trations of triamcinolone acetonide. There are a
few patients in whom 0.5 per cent seems to work
faster or perhaps better but the price to the
patient is so high ($8.00 per half ounce) that not
many will feel that the advantages are worth
the cost. At the suggestion of A. B. Lerner, we
compared 0.01 per cent to 0.1 per cent and
were surprised to find that there was only a
slight diminution in activity when one used
1/10 the concentration in present market prepa-
rations. At the top of Table 6 are the results
from a previous publication (16) of a similar
comparison which demonstrated a superiority
of 0.1 per cent triamcinolone acetonide over 1.0
per cent hydrocortisone. In the lower half are
new results which we think have far reaching
significance. These data show that 0.01 per cent
triarncinolone acetonide lotion is not only as
good as the usual 1.0 per cent hydrocortisone
lotion but if anything better. As a result of this
observation patients have been able to afford
corticosteroid creams in pound quantities. By
applying the medication frequently and freely
over large areas of the body it has become much
easier to control widespread areas of dermatitis
without systemic corticosteroids. The full
implications of the observation that the 10 times
diluted triamcinolone acetonide is more effective
than the regular 1 per cent hydrocortisone will
not be realized until dermatologists learn to use
the effective, safe and inexpensive preparations
freely in large quantities.
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